Intranasal gene delivery for treating Parkinsons disease: Overcoming the blood-brain barrier

Expert Opinion on Drug Delivery

Volumn 12, Issue 12, 2015, Pages 1923-1941

  Aly, Amirah E E ^a   Waszczak, Barbara L ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

DNA nanoparticles; gene therapy; glial cell line derived neurotrophic factor; intranasal delivery; Parkinson's disease; pericytes

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; DAVUNETIDE; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH DIFFERENTIATION FACTOR 5; INSULIN; NANOCARRIER; NERVE GROWTH FACTOR; NEUROPEPTIDE Y; NEURTURIN; OREXIN; OSTEOPONTIN; OXYTOCIN; VASCULOTROPIN; VIRUS VECTOR; DRUG;

BLOOD BRAIN BARRIER; DISEASE COURSE; DOPAMINERGIC NERVE CELL; GENE VECTOR; HUMAN; MACROMOLECULE; NEUROPROTECTION; PARKINSON DISEASE; REVIEW; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENE THERAPY; GENE TRANSFER; INTRANASAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, INTRANASAL; ANIMALS; BLOOD-BRAIN BARRIER; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; NEURTURIN; PARKINSON DISEASE; PHARMACEUTICAL PREPARATIONS;

EID: 84959463237     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2015.1069815     Document Type: Review

References (181)

1. Dhuria SV, Hanson LR, Frey WH II. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010;99(4):1654-73
2. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012;64(7):614-28
3. Malerba F, Paoletti F, Capsoni S, et al. Intranasal delivery of therapeutic proteins for neurological diseases. Expert Opin Drug Deliv 2011;8(10):1277-96
4. Tayebati SK, Nwankwo IE, Amenta F. Intranasal drug delivery to the central nervous system: present status and future outlook. Curr Pharm Des 2013;19(3):510-26
5. Frey WH II. Bypassing the blood-brain barrier to deliver thereapeutic agents to the brain and spinal cord. Drug Del Tech 2002;2:46-9
6. Balin BJ, Broadwell RD, Salcman M, et al. Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J Comp Neurol 1986;251(2):260-80
7. Thorne RG, Pronk GJ, Padmanabhan V, et al. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004;127(2):481-96
8. Thorne RG, Hanson LR, Ross TM, et al. Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience 2008;152(3):785-97
9. Migliore MM, Vyas TK, Campbell RB, et al. Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations. J Pharm Sci 2010;99(4):1745-61
10. Hadaczek P, Yamashita Y, Mirek H, et al. The 'perivascular pump' driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol Ther 2006;14(1):69-78
11. Thorne RG, Frey WH II. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 2001;40(12):907-46
12. Bender TS, Migliore MM, Campbell RB, et al. Intranasal administration of glial-derived neurotrophic factor (GDNF) rapidly and significantly increases whole-brain GDNF level in rats. Neuroscience 2015;303:569-76
13. Lin LF, Doherty DH, Lile JD, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260(5111):1130-2
14. Lin LF, Zhang TJ, Collins F, et al. Purification and initial characterization of rat B49 glial cell line-derived neurotrophic factor. J Neurochem 1994;63(2):758-68
15. Sakane T, Akizuki M, Taki Y, et al. Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the molecular weight of drugs. J Pharm Pharmacol 1995;47(5):379-81
16. Born J, Lange T, Kern W, et al. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002;5(6):514-16
17. Renner DB, Svitak AL, Gallus NJ, et al. Intranasal delivery of insulin via the olfactory nerve pathway. J Pharm Pharmacol 2012;64(12):1709-14
18. Ross TM, Martinez PM, Renner JC, et al. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a noninvasive treatment strategy for multiple sclerosis. J Neuroimmunol 2004;151(1-2):66-77
19. Alcala-Barraza SR, Lee MS, Hanson LR, et al. Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J Drug Target 2010;18(3):179-90
20. Frey WH, Liu J, Chen X, et al. Delivery of 125I-NGF to the Brain via the Olfactory Route. Drug Deliv 1997;4(2):87-92
21. Chen XQ, Fawcett JR, Rahman YE, et al. Delivery of Nerve Growth Factor to the Brain via the Olfactory Pathway. J Alzheimers Dis 1998;1(1):35-44
22. Zhao YZ, Li X, Lu CT, et al. Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats. Nanomedicine 2014;10(4):755-64
23. Doyle KP, Yang T, Lessov NS, et al. Nasal administration of osteopontin peptide mimetics confers neuroprotection in stroke. J Cereb Blood Flow Metab 2008;28(6):1235-48
24. Topkoru BC, Altay O, Duris K, et al. Nasal administration of recombinant osteopontin attenuates early brain injury after subarachnoid hemorrhage. Stroke 2013;44(11):3189-94
25. Gozes I, Giladi E, Pinhasov A, et al. Activity-dependent neurotrophic factor: intranasal administration of femtomolaracting peptides improve performance in a water maze. J Pharmacol Exp Ther 2000;293(3):1091-8
26. Lacroix JS, Ricchetti AP, Morel D, et al. Intranasal administration of neuropeptide Y in man: systemic absorption and functional effects. Br J Pharmacol 1996;118(8):2079-84
27. Serova LI, Tillinger A, Alaluf LG, et al. Single intranasal neuropeptide Y infusion attenuates development of PTSD-like symptoms to traumatic stress in rats. Neuroscience 2013;236:298-312
28. Hanson LR, Fine JM, Hoekman JD, et al. Intranasal delivery of growth differentiation factor 5 to the central nervous system. Drug Deliv 2012;19(3):149-54
29. Yang JP, Liu HJ, Cheng SM, et al. Direct transport of VEGF from the nasal cavity to brain. Neurosci Lett 2009;449(2):108-11
30. Migliore MM, Ortiz R, Dye S, et al. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease. Neuroscience 2014;274:11-23
31. Kordower JH, Bjorklund A. Trophic factor gene therapy for Parkinson's disease. Mov Disord 2013;28(1):96-109
32. Hegarty SV, O'Keeffe GW, Sullivan AM. Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease. Neural Regen Res 2014;9(19):1708-11
33. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006;59(3):459-66
34. Sullivan AM, Opacka-Juffry J, Pohl J, et al. Neuroprotective effects of growth/differentiation factor 5 depend on the site of administration. Brain Res 1999;818(1):176-9
35. Sullivan AM, O'Keeffe GW. The role of growth/differentiation factor 5 (GDF5) in the induction and survival of midbrain dopaminergic neurones: relevance to Parkinson's disease treatment. J Anat 2005;207(3):219-26
36. Hurley FM, Costello DJ, Sullivan AM. Neuroprotective effects of delayed administration of growth/differentiation factor-5 in the partial lesion model of Parkinson's disease. Exp Neurol 2004;185(2):281-9
37. Freiherr J, Hallschmid M, Frey WH II, et al. Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 2013;27(7):505-14
38. Reger MA, Watson GS, Frey WH II, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 2006;27(3):451-8
39. Benedict C, Hallschmid M, Hatke A, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004;29(10):1326-34
40. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69(1):29-38
41. Bohringer A, Schwabe L, Richter S, et al. Intranasal insulin attenuates the hypothalamic-pituitary-adrenal axis response to psychosocial stress. Psychoneuroendocrinology 2008;33(10):1394-400
42. Novak P. Treatment of parkinson disease and multiple system atrophy using intranasal insulin. 2014. Available from: https://clinicaltrials. gov/ct2/show/record/NCT02064166
43. Benarroch EE. Insulin-like growth factors in the brain and their potential clinical implications. Neurology 2012;79(21):2148-53
44. O'Kusky J, Ye P. Neurodevelopmental effects of insulin-like growth factor signaling. Front Neuroendocrinol 2012;33(3):230-51
45. Quesada A, Romeo HE, Micevych P. Distribution and localization patterns of estrogen receptor-beta and insulin-like growth factor-1 receptors in neurons and glial cells of the female rat substantia nigra: localization of ERbeta and IGF-1R in substantia nigra. J Comp Neurol 2007;503(1):198-208
46. Quesada A, Micevych PE. Estrogen interacts with the IGF-1 system to protect nigrostriatal dopamine and maintain motoric behavior after 6-hydroxdopamine lesions. J Neurosci Res 2004;75(1):107-16
47. Parr LA, Modi M, Siebert E, et al. Intranasal oxytocin selectively attenuates rhesus monkeys' attention to negative facial expressions. Psychoneuroendocrinology 2013;38(9):1748-56
48. Guastella AJ, Einfeld SL, Gray KM, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 2010;67(7):692-4
49. Domes G, Sibold M, Schulze L, et al. Intranasal oxytocin increases covert attention to positive social cues. Psychol Med 2013;43(8):1747-53
50. Cardoso C, Ellenbogen MA, Linnen AM. Acute intranasal oxytocin improves positive self-perceptions of personality. Psychopharmacology (Berl) 2012;220(4):741-9
51. Smith AS, Agmo A, Birnie AK, et al. Manipulation of the oxytocin system alters social behavior and attraction in pair-bonding primates, Callithrix penicillata. Horm Behav 2010;57(2):255-62
52. Cardoso C, Ellenbogen MA, Orlando MA, et al. Intranasal oxytocin attenuates the cortisol response to physical stress: a dose-response study. Psychoneuroendocrinology 2013;38(3):399-407
53. Calcagnoli F, Kreutzmann JC, de Boer SF, et al. Acute and repeated intranasal oxytocin administration exerts anti-aggressive and pro-affiliative effects in male rats. Psychoneuroendocrinology 2015;51:112-21
54. Pedersen CA, Smedley KL, Leserman J, et al. Intranasal oxytocin blocks alcohol withdrawal in human subjects. Alcohol Clin Exp Res 2013;37(3):484-9
55. Feifel D, Macdonald K, Nguyen A, et al. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry 2010;68(7):678-80
56. Feifel D, Macdonald K, Cobb P, et al. Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia. Schizophr Res 2012;139(1-3):207-10
57. Davis MC, Lee J, Horan WP, et al. Effects of single dose intranasal oxytocin on social cognition in schizophrenia. Schizophr Res 2013;147(2-3):393-7
58. Evans SL, Dal Monte O, Noble P, et al. Intranasal oxytocin effects on social cognition: a critique. Brain Res 2014;1580:69-77
59. Freeman SM, Inoue K, Smith AL, et al. The neuroanatomical distribution of oxytocin receptor binding and mRNA in the male rhesus macaque (Macaca mulatta). Psychoneuroendocrinology 2014;45:128-41
60. Jin K, Xie L, Childs J, et al. Cerebral neurogenesis is induced by intranasal administration of growth factors. Ann Neurol 2003;53(3):405-9
61. Sleeman IJ, Boshoff EL, Duty S. Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Neuropharmacology 2012;63(7):1268-77
62. Murer MG, Yan Q, Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 2001;63(1):71-124
63. Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 2011;10(3):209-19
64. Kaplan GB, Vasterling JJ, Vedak PC. Brain-derived neurotrophic factor in traumatic brain injury, post-traumatic stress disorder, and their comorbid conditions: role in pathogenesis and treatment. Behav Pharmacol 2010;21(5-6):427-37
65. Yulug B, Ozan E, Gonul AS, et al. Brain-derived neurotrophic factor, stress and depression: a minireview. Brain Res Bull 2009;78(6):267-9
66. Chen A, Xiong LJ, Tong Y, et al. The neuroprotective roles of BDNF in hypoxic ischemic brain injury. Biomed Rep 2013;1(2):167-76
67. Jiang Y, Wei N, Lu T, et al. Intranasal brain-derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats. Neuroscience 2011;172:398-405
68. Hyman C, Hofer M, Barde YA, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991;350(6315):230-2
69. Stahl K, Mylonakou MN, Skare O, et al. Cytoprotective effects of growth factors: BDNF more potent than GDNF in an organotypic culture model of Parkinson's disease. Brain Res 2011;1378:105-18
70. Frim DM, Uhler TA, Galpern WR, et al. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994;91(11):5104-8
71. Levivier M, Przedborski S, Bencsics C, et al. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 1995;15(12):7810-20
72. Tsukahara T, Takeda M, Shimohama S, et al. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridineinduced parkinsonism in monkeys. Neurosurgery 1995;37(4):733-9; discussion 39-41
73. Sobreviela T, Clary DO, Reichardt LF, et al. TrkA-immunoreactive profiles in the central nervous system: colocalization with neurons containing p75 nerve growth factor receptor, choline acetyltransferase, and serotonin. J Comp Neurol 1994;350(4):587-611
74. Yan Q, Matheson C, Sun J, et al. Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression. Exp Neurol 1994;127(1):23-36
75. Sanchez-Ortiz E, Yui D, Song D, et al. TrkA gene ablation in basal forebrain results in dysfunction of the cholinergic circuitry. J Neurosci 2012;32(12):4065-79
76. De Rosa R, Garcia AA, Braschi C, et al. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci USA 2005;102(10):3811-16
77. Capsoni S, Marinelli S, Ceci M, et al. Intranasal 'painless' human Nerve Growth Factor [corrected] slows amyloid neurodegeneration and prevents memory deficits in App X PS1 mice. PLoS One 2012;7(5):e37555
78. Lv Q, Lan W, Sun W, et al. Intranasal nerve growth factor attenuates tau phosphorylation in brain after traumatic brain injury in rats. J Neurol Sci 2014;345(1-2):48-55
79. Tian L, Guo R, Yue X, et al. Intranasal administration of nerve growth factor ameliorate beta-amyloid deposition after traumatic brain injury in rats. Brain Res 2012;1440:47-55
80. Lv Q, Fan X, Xu G, et al. Intranasal delivery of nerve growth factor attenuates aquaporins-4-induced edema following traumatic brain injury in rats. Brain Res 2013;1493:80-9
81. Zhu W, Cheng S, Xu G, et al. Intranasal nerve growth factor enhances striatal neurogenesis in adult rats with focal cerebral ischemia. Drug Deliv 2011;18(5):338-43
82. Zhao HM, Liu XF, Mao XW, et al. Intranasal delivery of nerve growth factor to protect the central nervous system against acute cerebral infarction. Chin Med Sci J 2004;19(4):257-61
83. Melchior B, Nerriere-Daguin V, Laplaud DA, et al. Ectopic expression of the TrkA receptor in adult dopaminergic mesencephalic neurons promotes retrograde axonal NGF transport and NGF-dependent neuroprotection. Exp Neurol 2003;183(2):367-78
84. Gozes I, Alcalay R, Giladi E, et al. NAP accelerates the performance of normal rats in the water maze. J Mol Neurosci 2002;19(1-2):167-70
85. Matsuoka Y, Gray AJ, Hirata-Fukae C, et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 2007;31(2):165-70
86. Morimoto BH, Schmechel D, Hirman J, et al. A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment. Dement Geriatr Cogn Disord 2013;35(5-6):325-36
87. Sharma NK, Sethy NK, Meena RN, et al. Activity-dependent neuroprotective protein (ADNP)-derived peptide (NAP) ameliorates hypobaric hypoxia induced oxidative stress in rat brain. Peptides 2011;32(6):1217-24
88. Fleming SM, Mulligan CK, Richter F, et al. A pilot trial of the microtubuleinteracting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Mol Cell Neurosci 2011;46(3):597-606
89. Magen I, Ostritsky R, Richter F, et al. Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing alpha-synuclein. Pharmacol Res Perspect 2014;2(5):e00065
90. Dhuria SV, Hanson LR, Frey WH. 2nd. Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J Pharm Sci 2009;98(7):2501-15
91. Deadwyler SA, Porrino L, Siegel JM, et al. Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 2007;27(52):14239-47
92. Baier PC, Hallschmid M, Seeck-Hirschner M, et al. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med 2011;12(10):941-6
93. Weinhold SL, Seeck-Hirschner M, Nowak A, et al. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy. Behav Brain Res 2014;262:8-13
94. Baier PC, Weinhold SL, Huth V, et al. Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1). Brain 2008;131(Pt 10):2734-41
95. Fronczek R, Overeem S, Lee SY, et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007;130(Pt 6):1577-85
96. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007;130(Pt 6):1586-95
97. Wienecke M, Werth E, Poryazova R, et al. Progressive dopamine and hypocretin deficiencies in Parkinson's disease: is there an impact on sleep and wakefulness J Sleep Res 2012;21(6):710-17
98. Feng Y, Liu T, Li XQ, et al. Neuroprotection by Orexin-A via HIF-1alpha induction in a cellular model of Parkinson's disease. Neurosci Lett 2014;579:35-40
99. Guerreiro S, Florence C, Rousseau E, et al. The sleep-modulating peptide orexin-B protects midbrain dopamine neurons from degeneration, alone or in cooperation with nicotine. Mol Pharmacol 2015;87(3):525-32
100. Vergara C, Ramirez B. CNTF, a pleiotropic cytokine: emphasis on its myotrophic role. Brain Res Brain Res Rev 2004;47(1-3):161-73
101. Sleeman MW, Anderson KD, Lambert PD, et al. The ciliary neurotrophic factor and its receptor, CNTFR alpha. Pharm Acta Helv 2000;74(2-3):265-72
102. Adler R, Landa KB, Manthorpe M, et al. Cholinergic neuronotrophic factors: intraocular distribution of trophic activity for ciliary neurons. Science 1979;204(4400):1434-6
103. Kordower JH, Yaping C, Maclennan AJ. Ciliary neurotrophic factor receptor alpha-immunoreactivity in the monkey central nervous system. J Comp Neurol 1997;377(3):365-80
104. Hagg T, Varon S. Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. Proc Natl Acad Sci USA 1993;90(13):6315-19
105. Shapiro L, Zhang XX, Rupp RG, et al. Ciliary neurotrophic factor is an endogenous pyrogen. Proc Natl Acad Sci USA 1993;90(18):8614-18
106. Kelly JF, Elias CF, Lee CE, et al. Ciliary neurotrophic factor and leptin induce distinct patterns of immediate early gene expression in the brain. Diabetes 2004;53(4):911-20
107. Genc S, Zadeoglulari Z, Oner MG, et al. Intranasal erythropoietin therapy in nervous system disorders. Expert Opin Drug Deliv 2011;8(1):19-32
108. Rodriguez Cruz Y, Mengana Tamos Y, Munoz Cernuda A, et al. Treatment with nasal neuro-EPO improves the neurological, cognitive, and histological state in a gerbil model of focal ischemia. ScientificWorldJournal 2010;10:2288-300
109. Yu YP, Xu QQ, Zhang Q, et al. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett 2005;387(1):5-10
110. Merelli A, Caltana L, Lazarowski A, et al. Experimental evidence of the potential use of erythropoietin by intranasal administration as a neuroprotective agent in cerebral hypoxia. Drug Metabol Drug Interact 2011;26(2):65-9
111. Zhao HW, Lu Y, Li XY, et al. Intranasal administration of low dosage recombinant human erythropoietin inhibits seizure in rats. Zhejiang Da Xue Xue Bao Yi Xue Ban 2009;38(6):565-71
112. Maurice T, Mustafa MH, Desrumaux C, et al. Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Abeta(2)(5)(-)(3)(5) nontransgenic mouse model of Alzheimer's disease. J Psychopharmacol 2013;27(11):1044-57
113. Ganser C, Papazoglou A, Just L, et al. Neuroprotective effects of erythropoietin on 6-hydroxydopamine-treated ventral mesencephalic dopamine-rich cultures. Exp Cell Res 2010;316(5):737-46
114. Qi C, Xu M, Gan J, et al. Erythropoietin improves neurobehavior by reducing dopaminergic neuron loss in a 6hydroxydopamineinduced rat model. Int J Mol Med 2014;34(2):440-50
115. Erbas O, Cinar BP, Solmaz V, et al. The neuroprotective effect of erythropoietin on experimental Parkinson model in rats. Neuropeptides 2015;49:1-5
116. Denhardt DT, Giachelli CM, Rittling SR. Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol 2001;41:723-49
117. Denhardt DT, Noda M, O'Regan AW, et al. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001;107(9):1055-61
118. Meller R, Stevens SL, Minami M, et al. Neuroprotection by osteopontin in stroke. J Cereb Blood Flow Metab 2005;25(2):217-25
119. Iczkiewicz J, Broom L, Cooper JD, et al. The RGD-containing peptide fragment of osteopontin protects tyrosine hydroxylase positive cells against toxic insult in primary ventral mesencephalic cultures and in the rat substantia nigra. J Neurochem 2010;114(6):1792-804
120. Broom L, Jenner P, Rose S. Increased neurotrophic factor levels in ventral mesencephalic cultures do not explain the protective effect of osteopontin and the synthetic 15-mer RGD domain against MPP+ toxicity. Exp Neurol 2015;263:1-7
121. Wolak T. Osteopontin-a multi-modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis 2014;236(2):327-37
122. Jan HJ, Lee CC, Shih YL, et al. Osteopontin regulates human glioma cell invasiveness and tumor growth in mice. Neuro Oncol 2010;12(1):58-70
123. Jin K, Zhu Y, Sun Y, et al. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 2002;99(18):11946-50
124. Falk T, Gonzalez RT, Sherman SJ. The yin and yang of VEGF and PEDF: multifaceted neurotrophic factors and their potential in the treatment of Parkinson's Disease. Int J Mol Sci 2010;11(8):2875-900
125. Schoch HJ, Fischer S, Marti HH. Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain 2002;125(Pt 11):2549-57
126. Harrigan MR, Ennis SR, Sullivan SE, et al. Effects of intraventricular infusion of vascular endothelial growth factor on cerebral blood flow, edema, and infarct volume. Acta Neurochir (Wien) 2003;145(1):49-53
127. Li Y, Zhang F, Nagai N, et al. VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. J Clin Invest 2008;118(3):913-23
128. Yasuhara T, Shingo T, Kobayashi K, et al. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease. Eur J Neurosci 2004;19(6):1494-504
129. Yasuhara T, Shingo T, Muraoka K, et al. Neurorescue effects of VEGF on a rat model of Parkinson's disease. Brain Res 2005;1053(1-2):10-18
130. Falk T, Yue X, Zhang S, et al. Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease. Neurosci Lett 2011;496(1):43-7
131. Yue X, Hariri DJ, Caballero B, et al. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease. Neuroscience 2014;258:385-400
132. Herran E, Requejo C, Ruiz-Ortega JA, et al. Increased antiparkinson efficacy of the combined administration of VEGFand GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease. Int J Nanomedicine 2014;9:2677-87
133. Yang JP, Liu HJ, Wang ZL, et al. The dose-effectiveness of intranasal VEGF in treatment of experimental stroke. Neurosci Lett 2009;461(3):212-16
134. Kaner RJ, Ladetto JV, Singh R, et al. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol 2000;22(6):657-64
135. Vahatalo LH, Ruohonen ST, Makela S, et al. Neuropeptide Y in the noradrenergic neurones induces obesity and inhibits sympathetic tone in mice. Acta Physiol (Oxf) 2015;213(4):902-19
136. Sohn JW. Network of hypothalamic neurons that control appetite. BMB Rep 2015;48(4):229-33
137. Cohen H, Liu T, Kozlovsky N, et al. The neuropeptide Y (NPY)-ergic system is associated with behavioral resilience to stress exposure in an animal model of post-traumatic stress disorder. Neuropsychopharmacology 2012;37(2):350-63
138. Malva JO, Xapelli S, Baptista S, et al. Multifaces of neuropeptide Y in the brain-neuroprotection, neurogenesis and neuroinflammation. Neuropeptides 2012;46(6):299-308
139. Serova LI, Laukova M, Alaluf LG, et al. Intranasal neuropeptide Y reverses anxiety and depressive-like behavior impaired by single prolonged stress PTSD model. Eur Neuropsychopharmacol 2014;24(1):142-7
140. Laukova M, Alaluf LG, Serova LI, et al. Early intervention with intranasal NPY prevents single prolonged stress-triggered impairments in hypothalamus and ventral hippocampus in male rats. Endocrinology 2014;155(10):3920-33
141. Decressac M, Pain S, Chabeauti PY, et al. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease. Neurobiol Aging 2012;33(9):2125-37
142. Draghia R, Caillaud C, Manicom R, et al. Gene delivery into the central nervous system by nasal instillation in rats. Gene Ther 1995;2(6):418-23
143. Broberg EK, Peltoniemi J, Nygardas M, et al. Spread and replication of and immune response to gamma134. 5-negative herpes simplex virus type 1 vectors in BALB/c mice. J Virol 2004;78(23):13139-52
144. Jiang Y, Wei N, Zhu J, et al. A new approach with less damage: intranasal delivery of tetracycline-inducible replication-defective herpes simplex virus type-1 vector to brain. Neuroscience 2012;201:96-104
145. Laing JM, Gober MD, Golembewski EK, et al. Intranasal administration of the growthcompromised HSV-2 vector DeltaRR prevents kainate-induced seizures and neuronal loss in rats and mice. Mol Ther 2006;13(5):870-81
146. Wolf DA, Hanson LR, Aronovich EL, et al. Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration. Mol Genet Metab 2012;106(1):131-4
147. Han IK, Kim MY, Byun HM, et al. Enhanced brain targeting efficiency of intranasally administered plasmid DNA: an alternative route for brain gene therapy. J Mol Med (Berl) 2007;85(1):75-83
148. Liu G, Li D, Pasumarthy MK, et al. Nanoparticles of compacted DNA transfect postmitotic cells. J Biol Chem 2003;278(35):32578-86
149. Fink TL, Klepcyk PJ, Oette SM, et al. Plasmid size up to 20[thinsp]kbp does not limit effective in vivo lung gene transfer using compacted DNA nanoparticles. Gene Ther 2006;13(13):1048-51
150. Ziady AG, Gedeon CR, Miller T, et al. Transfection of airway epithelium by stable PEGylated poly-L-lysine DNA nanoparticles in vivo. Mol Ther 2003;8(6):936-47
151. Yurek DM, Fletcher AM, Smith GM, et al. Long-term transgene expression in the central nervous system using DNA nanoparticles. Mol Ther 2009;17(4):641-50
152. Ding XQ, Quiambao AB, Fitzgerald JB, et al. Ocular delivery of compacted DNA-nanoparticles does not elicit toxicity in the mouse retina. PLoS One 2009;4(10):e7410
153. Farjo R, Skaggs J, Quiambao AB, et al. Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS ONE 2006;1:e38
154. Yurek DM, Fletcher AM, McShane M, et al. DNA nanoparticles: detection of long-term transgene activity in brain using bioluminescence imaging. Mol Imaging 2011;10(5):327-39
155. Harmon BT, Aly AE, Padegimas L, et al. Intranasal administration of plasmid DNA nanoparticles yields successful transfection and expression of a reporter protein in rat brain. Gene Ther 2014;21(5):514-21
156. Aly AE, Harmon BT, Shah P, et al. Widespread expression of GDNF throughout rat brain after intranasal delivery of hGDNF plasmid nanoparticles. Cell Transplant 2015;24(4):752-3
157. Fletcher AM, Kowalczyk TH, Padegimas L, et al. Transgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell linederived neurotrophic factor. Neuroscience 2011;194:220-6
158. Harmon BT, Aly AE, Christodoulou A, et al. Intranasal delivery of pGDNF nanoparticles provides neuroprotection in the rat 6-hydroxydopamine model of Parkinson's disease. Soc Neurosci Abstr 2013;#46. 15
159. Harmon BT. Intranasal delivery of pGDNF nanoparticles for Parkinson's Disease. ProQuest LLC 2013; UMI Dissertation Publishing, UMI 3594468
160. Aly AE-E, Harmon BT, Dines K, et al. Intranasal Delivery of hGDNF nanoparticles results in GDNF expression throughout rat brain and provides neuroprotection tin the rat 6-hydroxydopamine model of Parkinson's disease. Cell Transplant 2014;23(6):762-3
161. Horger BA, Nishimura MC, Armanini MP, et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 1998;18(13):4929-37
162. Rosenblad C, Kirik D, Devaux B, et al. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur J Neurosci 1999;11(5):1554-66
163. Petrova P, Raibekas A, Pevsner J, et al. MANF: a new mesencephalic, astrocytederived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci 2003;20(2):173-88
164. Lindholm P, Voutilainen MH, Lauren J, et al. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 2007;448(7149):73-7
165. Voutilainen MH, Back S, Porsti E, et al. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. J Neurosci 2009;29(30):9651-9
166. Voutilainen MH, Back S, Peranen J, et al. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. Exp Neurol 2011;228(1):99-108
167. Airavaara M, Voutilainen MH, Wang Y, et al. Neurorestoration. Parkinsonism Relat Disord 2012;18(Suppl 1):S143-6
168. Murlidharan G, Samulski RJ, Asokan A. Biology of adeno-associated viral vectors in the central nervous system. Front Mol Neurosci 2014;7:76
169. Tenenbaum L, Chtarto A, Lehtonen E, et al. Recombinant AAV-mediated gene delivery to the central nervous system. J Gene Med 2004;6 Suppl 1:S212-22
170. Bartus RT, Brown L, Wilson A, et al. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis 2011;44(1):38-52
171. Tian YY, Tang CJ, Wang JN, et al. Favorable effects of VEGF gene transfer on a rat model of Parkinson disease using adeno-associated viral vectors. Neurosci Lett 2007;421(3):239-44
172. Back S, Peranen J, Galli E, et al. Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease. Brain Behav 2013;3(2):75-88
173. Ren X, Zhang T, Gong X, et al. AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model. Exp Neurol 2013;248:148-56
174. Puskovic V, Wolfe D, Wechuck J, et al. HSV-mediated delivery of erythropoietin restores dopaminergic function in MPTP-treated mice. Mol Ther 2006;14(5):710-15
175. Xue YQ, Ma BF, Zhao LR, et al. AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson's disease. Gene Ther 2010;17(1):83-94
176. Lopes C, Ribeiro M, Duarte AI, et al. IGF-1 intranasal administration rescues Huntington's disease phenotypes in YAC128 mice. Mol Neurobiol 2014;49(3):1126-42
177. Lin S, Fan LW, Rhodes PG, et al. Intranasal administration of IGF-1 attenuates hypoxic-ischemic brain injury in neonatal rats. Exp Neurol 2009;217(2):361-70
178. Liu XF, Fawcett JR, Hanson LR, et al. The window of opportunity for treatment of focal cerebral ischemic damage with noninvasive intranasal insulin-like growth factor-I in rats. J Stroke Cerebrovasc Dis 2004;13(1):16-23
179. Cai Z, Fan LW, Lin S, et al. Intranasal administration of insulin-like growth factor-1 protects against lipopolysaccharide-induced injury in the developing rat brain. Neuroscience 2011;194:195-207
180. Domes G, Heinrichs M, Kumbier E, et al. Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder. Biol Psychiatry 2013;74(3):164-71
181. Scafidi J, Hammond TR, Scafidi S, et al. Intranasal epidermal growth factor treatment rescues neonatal brain injury. Nature 2014;506(7487):230-4